Related Experiment Video
Updated: May 6, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Increased risk of acute myocardial infarction in systemic sclerosis: a nationwide population-based study
Szu-Ying Chu1, Yi-Ju Chen, Chia-Jen Liu
1Department of Dermatology, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Dermatology, National Yang-Ming University, Taipei, Taiwan; Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan.
Insights
Systemic sclerosis significantly increases the risk of acute myocardial infarction. Current immunosuppressors did not demonstrate a reduced risk in patients with this autoimmune condition.
Area of Science:
- Cardiology
- Rheumatology
- Epidemiology
Background:
- Systemic sclerosis (SSc) is a severe autoimmune disease with high rates of cardiac involvement.
- Acute myocardial infarction (AMI) risk in SSc patients lacks large-scale epidemiological data.
- Vasculopathy in SSc contributes to myocardial damage.
Purpose of the Study:
- To assess the hazard ratio (HR) for AMI in SSc patients.
- To identify risk factors for AMI in SSc.
- To compare AMI risk among SSc patients using different immunosuppressors.
Main Methods:
- A cohort of 1344 SSc patients and 13,440 matched controls (1997-2006) from Taiwan's National Health Insurance Research Database.
- Cox proportional hazards model used to calculate adjusted HRs for AMI.
- Comparison of AMI risk between SSc patients on immunosuppressors versus those not on them.
Main Results:
- SSc is an independent risk factor for AMI (adjusted HR 2.45).
- Hypertension (HR 2.08) and diabetes (HR 2.14) were significant risk factors for AMI.
- Immunosuppressors (steroids, penicillamine, cyclophosphamide, azathioprine, methotrexate, cyclosporine) did not reduce AMI risk in SSc patients.
Conclusions:
- Systemic sclerosis is independently linked to a higher risk of acute myocardial infarction.
- Current immunosuppressive therapies do not appear to mitigate AMI risk in SSc patients.
- Further research is needed to understand and manage cardiovascular risk in SSc.
Purpose:
Systemic sclerosis is a life-threatening autoimmune disease characterized by vasculopathy, which results in myocardial involvement in an extremely high percentage of patients. Nevertheless, there have been no large-scale epidemiological studies about the risk of acute myocardial infarction in patients with systemic sclerosis. The aims of this study were to evaluate the hazard ratio (HR) and risk factors of acute myocardial infarction in patients with systemic sclerosis, as well as to compare the risks of acute myocardial infarction among systemic sclerosis patients taking different immunosuppressors.
Methods:
The study cohort included 1344 patients with systemic sclerosis and 13,440 (1:10) age-, sex-, and comorbidity-matched controls during the period between 1997 and 2006, from the National Health Insurance Research Database. We compared the risk of acute myocardial infarction between patients with systemic sclerosis and controls and calculated the adjusted HRs for acute myocardial infarction in systemic sclerosis patients taking immunosuppressors and not taking immunosuppressors.
Results:
The incidence rates of acute myocardial infarction were 535 and 313 cases per 100,000 person-years for systemic sclerosis cohort and reference cohort, respectively (P <.001, unadjusted). After adjusting for age, sex, and underlying medical diseases on Cox proportional hazards model, systemic sclerosis was found to be an independent risk factor for acute myocardial infarction (HR 2.45). Other risk factors included hypertension (HR 2.08) and diabetes (HR 2.14). The multivariate adjusted HR for acute myocardial infarction did not decrease among the systemic sclerosis patients taking systemic steroids, penicillamine, cyclophosphamide, azathioprine, methotrexate, or cyclosporine.
Conclusion:
Systemic sclerosis is independently associated with an increased risk of acute myocardial infarction. Immunosuppressors do not lower the risk of acute myocardial infarction in our study.
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease I: Introduction
Coronary Artery Disease I: Introduction
Myocarditis I: Introduction
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Acute Coronary Syndrome III: Diagnostic Studies

